Literature DB >> 7807071

A systematic assessment of tricyclic antidepressants in the treatment of adult attention-deficit hyperactivity disorder.

T E Wilens1, J Biederman, E Mick, T J Spencer.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7807071     DOI: 10.1097/00005053-199501000-00010

Source DB:  PubMed          Journal:  J Nerv Ment Dis        ISSN: 0022-3018            Impact factor:   2.254


× No keyword cloud information.
  8 in total

Review 1.  Adult attention deficit hyperactivity disorder.

Authors:  S V Faraone; M T Tsuang
Journal:  Curr Psychiatry Rep       Date:  2001-04       Impact factor: 5.285

Review 2.  Non-stimulant treatments for ADHD.

Authors:  J Biederman; T Spencer
Journal:  Eur Child Adolesc Psychiatry       Date:  2000       Impact factor: 4.785

Review 3.  An update on the pharmacotherapy of attention-deficit/hyperactivity disorder in adults.

Authors:  Timothy E Wilens; Nicholas R Morrison; Jefferson Prince
Journal:  Expert Rev Neurother       Date:  2011-10       Impact factor: 4.618

Review 4.  Non-stimulant medications in the treatment of ADHD.

Authors:  Tobias Banaschewski; Veit Roessner; Ralf W Dittmann; Paramala Janardhanan Santosh; Aribert Rothenberger
Journal:  Eur Child Adolesc Psychiatry       Date:  2004       Impact factor: 4.785

5.  [Attention deficit hyperactivity disorder in adults. An overview].

Authors:  E Sobanski; B Alm
Journal:  Nervenarzt       Date:  2004-07       Impact factor: 1.214

Review 6.  [Multimodal treatment of adult attention-deficit hyperactivity disorder].

Authors:  C P Jacob; A Philipsen; D Ebert; J Deckert
Journal:  Nervenarzt       Date:  2008-07       Impact factor: 1.214

Review 7.  Drug therapy for adults with attention-deficit hyperactivity disorder.

Authors:  Timothy E Wilens
Journal:  Drugs       Date:  2003       Impact factor: 9.546

Review 8.  Treatment strategies for ADHD: an evidence-based guide to select optimal treatment.

Authors:  Arthur Caye; James M Swanson; David Coghill; Luis Augusto Rohde
Journal:  Mol Psychiatry       Date:  2018-06-28       Impact factor: 15.992

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.